Literature DB >> 4026878

Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes.

E R Korpi, D T Costakos, R J Wyatt.   

Abstract

An alcohol metabolite of haloperidol, reduced haloperidol, is present in the tissues of haloperidol-treated patients. We have studied whether rat and guinea pig liver microsomes have the capability to reduce haloperidol and thus serve as models for human haloperidol metabolism. Interestingly, the rat microsomes did not reduce haloperidol, but possessed an NADPH-dependent, carbon monoxide-inhibited mechanism to oxidize the reduced haloperidol back to haloperidol. Guinea pig microsomes efficiently reduced haloperidol molecules in a fashion not dependent on nicotinamide cofactors and not inhibited by carbon monoxide. Both of these activities were confined to the microsomal fraction. In guinea pigs, reduction of haloperidol was observed also in kidney slices, whereas brain slices proved inactive. Reduced haloperidol was also oxidized to haloperidol to a small extent in guinea pig microsomes. These in vitro experiments confirm our findings in vivo, which showed that in rats haloperidol is not reduced, while guinea pigs have a very active mechanism for reducing haloperidol. Thus, guinea pigs constitute a model for human haloperidol metabolism, and they should be used for further characterization of the reductive drug-metabolizing system.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4026878     DOI: 10.1016/0006-2952(85)90017-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.

Authors:  W H Chang; Y W Lam; M W Jann; H Chen
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?

Authors:  W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol.

Authors:  S J Porter; A A Somogyi; J M White
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

4.  Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol.

Authors:  D W Eyles; H A Whiteford; T J Stedman; S M Pond
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.

Authors:  M W Jann; Y W Lam; W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.

Authors:  B M Cohen; T Tsuneizumi; R J Baldessarini; A Campbell; S M Babb
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Synthesis of the enantiomers of reduced haloperidol.

Authors:  J C Jaen; B W Caprathe; S Priebe; L D Wise
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

8.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

Authors:  R F Tyndale; W Kalow; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

9.  Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in guinea pigs.

Authors:  W H Chang; S S Jaw; H S Wu; L Tsay; E K Yeh
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

10.  The measurement of haloperidol and reduced haloperidol in hair as an index of dosage history.

Authors:  H Matsuno; T Uematsu; M Nakashima
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.